- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02326597
Decision Aid for Therapeutic Options In Sickle Cell Disease
Comparative Effectiveness of a Decision Aid for Therapeutic Options in Sickle Cell Disease
Sickle cell disease (SCD) is an inherited disorder with chronic multi-system manifestations affecting 100,000 individuals in the US, largely of minority origin and associated with substantial morbidity, premature mortality, individual suffering, healthcare costs and loss of productivity. Disease modifying treatments such as hydroxyurea, chronic blood transfusion and curative bone marrow transplantation are offered to patients based on physician preference and current practice informed by clinical trials. Decision aids are tools that could help translate evidence from these sources into practice by helping clinicians involve patients in making deliberate choices based on accessible information about the options available and their outcomes and to help them make decisions based on their values and preferences.
The overarching goal of this project is to implement a web based decision aid individualized to patient characteristics to help patients with SCD achieve more accurate perception of risks and benefits of treatment options and make decisions in congruence with their values and preferences. Investigators will use a randomized controlled trial of the effectiveness of a web-based decision aid to give patients accurate information about risks and benefits of therapies that enable patients to make decisions based on their individual values and preferences.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Sickle cell disease (SCD) is an inherited disorder with chronic multi-system manifestations affecting 100,000 individuals in the US, largely of minority origin and associated with substantial morbidity, premature mortality, individual suffering, healthcare costs and loss of productivity. Disease modifying treatments such as hydroxyurea, chronic blood transfusion and curative bone marrow transplantation are offered to patients based on physician preference and current practice informed by clinical trials. Decision aids are tools that could help translate evidence from these sources into practice by helping clinicians involve patients in making deliberate choices based on accessible information about the options available and their outcomes and to help them make decisions based on their values and preferences.
There are minimal data about patient-related barriers to and attitudes towards, the use of curative therapies in SCD. Thus significant gaps remain in the understanding of patient perspectives, in the provision of accurate information about risks and benefits of therapies and of incorporating patients' values and preferences in offering treatment options. There is a need for research that helps to understand patient values and preferences and determines how to help patients make informed treatment decision in congruence with their values and preferences.
The overarching goal of this project is to implement a web based decision aid individualized to patient characteristics to help patients with SCD achieve more accurate perception of risks and benefits of treatment options and make decisions in congruence with their values and preferences. Investigators will use a randomized controlled trial of the effectiveness of a web-based decision aid to give patients accurate information about risks and benefits of therapies that enable patients to make decisions based on their individual values and preferences.
Investigators hypothesize that a web based decision aid individualized to patient characteristics can improve knowledge and help patients with SCD achieve more accurate perception of risks and benefits of treatment options and is associated with lower decisional conflict than standard care.
The aims of the study are to estimate the effectiveness of the decision aid tailored to individual patient characteristics on patient knowledge, patient involvement in decision-making and decision-making quality, when compared with usual care.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Individuals with sickle cell disease ages 8 to 80 years, inclusive OR
- Parent/legal guardian of patients (age < 18 years) with sickle cell disease who are directly involved in decision making regarding sickle cell disease healthcare treatment OR
- Health care provider directly involved in care of individuals with sickle cell disease, including child of parent/legal guardian enrolled in study
- Patients/parents/caregivers who have made a past decision to not obtain treatment of the considered option or who have not obtained treatment of the chosen option in past 12 months.
- All participants will be able to comprehend English
- Patients/Parent/Legal guardian will have access to the internet from iPad, smart phone or personal computer
Exclusion Criteria:
- Family Members/Individuals/Caregivers not directly involved in decision-making regarding sickle cell disease healthcare.
- Patient/parent/legal guardian who has already made a decision to begin and has started the treatment option.
- Child < 18 years of parent/legal guardian who is participating in Cohort A of this study and randomized to the control arm and not the decision aid arm.
- Spouse, significant other, or other family member involved in decision making for child <18 years if parent/legal guardian of child already enrolled into this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Standard Practice
Participants will receive education regarding treatment consideration from their healthcare provider/team as per standard practice (usual care).
|
Standard of care teaching and discussion regarding treatment options given by patient's healthcare provider.
|
EXPERIMENTAL: Standard Practice + Decision Aid
Participants will receive standard of care teaching and discussion in addition to web-based decision aid tool access.
|
Standard of care teaching and discussion regarding treatment options given by patient's healthcare provider.
The tool is a web based decision aid that provides information about the risks and benefits associated with sickle cell disease therapies.
Participants will be provided a unique access ID and password to access the information.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acceptability of Decision Aid Education Assessed by the Acceptability Survey
Time Frame: Post Visit 1 (Up to 2 Weeks)
|
Subjects will take an acceptability of education questionnaire which is a 8-item survey to assess the comprehension of education received for the decision aid tool.
Each item will be scored on a scale from 1-4 where 1=poor, 2=fair, 3=good, and 4=excellent.
Scores will be rated individually 1-4 according to each item.
There is no overall total score.
|
Post Visit 1 (Up to 2 Weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Decisional Self-Efficacy Scale Score
Time Frame: Month 3, Month 6
|
The Decision Self-Efficacy Scale measures self-confidence or belief in one's ability to make decisions, including participate in shared decision making.
Items are scored on a scale of 0-4 where 0 is not at all confident and 4 represents very confident.Total scores range from 0 (not at all confident) to 100 (very confident).
A score of 0 means 'extremely low self- efficacy' and a score of 100 means 'extremely high self-efficacy.
|
Month 3, Month 6
|
Mean Difference in Decisional Conflict Scale Scores
Time Frame: Baseline, Month 3
|
Decisional Conflict scale responses are scored for the total score, uncertainty sub-score, informed sub-score, values clarity sub-score, support sub-score and effective decision sub-score.
The total score ranges from 0 (no decisional conflict) to 100 (extremely high decisional conflict).
The uncertainty sub-score ranges from 0 (feels extremely certain about best choice) to 100 (feels extremely uncertain about best choice).
The informed sub-score ranges from 0 (feels extremely informed) to 100 (feels extremely uninformed).
The values clarity sub-score ranges from 0 (feels extremely clear about personal values for benefits & risks) to 100 (feels extremely unclear about personal values).
The support sub-score ranges from 0 (feels extremely supported in decision making) to 100 (feels extremely unsupported in decision making).
The effective decision sub-score ranges from 0 (good decision) to 100 (bad decision).
|
Baseline, Month 3
|
Mean Difference in Decisional Conflict Scale Scores
Time Frame: Baseline, Month 6
|
Decisional Conflict scale responses are scored for the total score, uncertainty sub-score, informed sub-score, values clarity sub-score, support sub-score and effective decision sub-score.
The total score ranges from 0 (no decisional conflict) to 100 (extremely high decisional conflict).
The uncertainty sub-score ranges from 0 (feels extremely certain about best choice) to 100 (feels extremely uncertain about best choice).
The informed sub-score ranges from 0 (feels extremely informed) to 100 (feels extremely uninformed).
The values clarity sub-score ranges from 0 (feels extremely clear about personal values for benefits & risks) to 100 (feels extremely unclear about personal values).
The support sub-score ranges from 0 (feels extremely supported in decision making) to 100 (feels extremely unsupported in decision making).
The effective decision sub-score ranges from 0 (good decision) to 100 (bad decision).
|
Baseline, Month 6
|
Mean Values Survey Score
Time Frame: Post Visit 1 (Up to 2 Weeks)
|
The values survey consists of 14 multiple choice questions to measure what is important to a patient when making decisions.
The patient decision aid will be tested in the twelve domains of the international patient decision aid standards collaboration criteria checklist.
Respondents will be asked to identify perceived importance of individual items (such as procedure related complications, decreasing complication risks, experiencing less pain) and to rate this importance on a 10 point likert scale (0-10) where 1 indicates "not important to me at all" and 10 indicates "extremely important to me".
Scores are then converted it to an 11 point scale and averaged.
|
Post Visit 1 (Up to 2 Weeks)
|
Mean Change in Preparation for Decision Making Scale Score
Time Frame: Month 3, Month 6
|
Preparation for Decision Making Scale assesses a patient's perception of how useful a decision aid or other decision support intervention is in preparing the respondent to communicate with their practitioner at a consultation focused on making a health decision.
The preparation for decision-making scale is scored on a 0-100 scale.
Higher scores indicate a higher perceived level of preparation for decision making.
The total score on the decision making scale is a continuous outcome.
|
Month 3, Month 6
|
Mean Knowledge Survey Scores
Time Frame: Baseline, Month 3, Month 6
|
Knowledge Survey is a 25 multiple choice questionnaire which assesses how much knowledge is being retained after information about risks is received.
The knowledge survey is scored as percent correct answers at each time point.
This is a set of questions to test knowledge and understanding about sickle cell disease and treatments.
As such the answers are dichotomous i.e true or false.
The total score of percent correct answers is scored in the range of 0-100%.
|
Baseline, Month 3, Month 6
|
Mean Decisional Regret Scale Score
Time Frame: Visit 3
|
Decision Regret Scale measures distress or remorse after a health care decision.
The subject rates regret using a 5 point Likert scale in answering the following questions; 1.
It was the right decision 2. I regret the decision 3. I would go for the same decision if I were to do it again 4. The decision caused me a lot of harm 5.
It was a wise decision.
Total scores range from 0 to 100.
A score of 0 means no regret; a score of 100 means high regret.
|
Visit 3
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Nouraie M, Lee JS, Zhang Y, Kanias T, Zhao X, Xiong Z, Oriss TB, Zeng Q, Kato GJ, Gibbs JS, Hildesheim ME, Sachdev V, Barst RJ, Machado RF, Hassell KL, Little JA, Schraufnagel DE, Krishnamurti L, Novelli E, Girgis RE, Morris CR, Rosenzweig EB, Badesch DB, Lanzkron S, Castro OL, Goldsmith JC, Gordeuk VR, Gladwin MT; Walk-PHASST Investigators and Patients. The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica. 2013 Mar;98(3):464-72. doi: 10.3324/haematol.2012.068965. Epub 2012 Sep 14.
- Wu CJ, Gladwin M, Tisdale J, Hsieh M, Law T, Biernacki M, Rogers S, Wang X, Walters M, Zahrieh D, Antin JH, Ritz J, Krishnamurti L. Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis. Br J Haematol. 2007 Nov;139(3):504-7. doi: 10.1111/j.1365-2141.2007.06803.x. No abstract available.
- Krishnamurti L, Kharbanda S, Biernacki MA, Zhang W, Baker KS, Wagner JE, Wu CJ. Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2008 Nov;14(11):1270-8. doi: 10.1016/j.bbmt.2008.08.016.
- Rao VK, Price S, Perkins K, Aldridge P, Tretler J, Davis J, Dale JK, Gill F, Hartman KR, Stork LC, Gnarra DJ, Krishnamurti L, Newburger PE, Puck J, Fleisher T. Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). Pediatr Blood Cancer. 2009 Jul;52(7):847-52. doi: 10.1002/pbc.21965.
- Aloe A, Krishnamurti L, Kladny B. Testing of collegiate athletes for sickle cell trait: what we, as genetic counselors should know. J Genet Couns. 2011 Aug;20(4):337-40. doi: 10.1007/s10897-011-9366-9. Epub 2011 Apr 19.
- Dovey S, Krishnamurti L, Sanfilippo J, Gunawardena S, Mclendon P, Campbell M, Alway S, Efymow B, Gracia C. Oocyte cryopreservation in a patient with sickle cell disease prior to hematopoietic stem cell transplantation: first report. J Assist Reprod Genet. 2012 Mar;29(3):265-9. doi: 10.1007/s10815-011-9698-2. Epub 2012 Jan 5.
- Kladny B, Williams A, Gupta A, Gettig EA, Krishnamurti L. Genetic counseling following the detection of hemoglobinopathy trait on the newborn screen is well received, improves knowledge, and relieves anxiety. Genet Med. 2011 Jul;13(7):658-61. doi: 10.1097/GIM.0b013e31821435f7.
- Long KA, Thomas SB, Grubs RE, Gettig EA, Krishnamurti L. Attitudes and beliefs of African-Americans toward genetics, genetic testing, and sickle cell disease education and awareness. J Genet Couns. 2011 Dec;20(6):572-92. doi: 10.1007/s10897-011-9388-3. Epub 2011 Jul 12.
- Krishnamurti L, Ross D, Sinha C, Leong T, Bakshi N, Mittal N, Veludhandi D, Pham AP, Taneja A, Gupta K, Nwanze J, Matthews AM, Joshi S, Vazquez Olivieri V, Arjunan S, Okonkwo I, Lukombo I, Lane P, Bakshi N, Loewenstein G. Comparative Effectiveness of a Web-Based Patient Decision Aid for Therapeutic Options for Sickle Cell Disease: Randomized Controlled Trial. J Med Internet Res. 2019 Dec 4;21(12):e14462. doi: 10.2196/14462.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00076096a
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sickle Cell Disease
-
Klein Buendel, Inc.National Institute on Minority Health and Health Disparities (NIMHD); Hilton...CompletedSickle Cell Disease | Sickle Cell Anemia in Children | Sickle Cell Thalassemia | Sickle Cell SC DiseaseUnited States
-
SangartCompletedSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseUnited Kingdom, France, Jamaica, Lebanon
-
Nova Laboratories LimitedCompletedSickle Cell Disease | Sickle Cell Hemoglobin C | Sickle Cell-beta-thalassemia | Sickle-Cell; Hemoglobin Disease, ThalassemiaUnited Kingdom, Jamaica
-
SangartWithdrawnSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseFrance, United Kingdom, Netherlands, Turkey, Bahrain, Belgium, Brazil, Lebanon, Qatar
-
University of British ColumbiaCompletedSickle Cell Disease | Beta-Thalassemia | Sickle Cell Trait | Sickle Cell-Beta Thalassemia | Sickle Cell-SS DiseaseCanada, Nepal
-
Sidney Kimmel Cancer Center at Thomas Jefferson...National Heart, Lung, and Blood Institute (NHLBI)TerminatedSickle Cell Anemia | Sickle Cell-hemoglobin C Disease | Sickle Cell-β0-thalassemiaUnited States
-
University of RegensburgRecruitingSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | HbS Disease | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SGermany, Austria
-
Centre Hospitalier Intercommunal CreteilRecruitingSickle-Cell Disease Nos With CrisisFrance
-
HemaQuest Pharmaceuticals Inc.TerminatedSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SUnited States, Lebanon, Egypt, Canada, Jamaica
-
HemaQuest Pharmaceuticals Inc.CompletedSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SUnited States, Lebanon, Canada, Egypt, Jamaica
Clinical Trials on Standard Practice
-
Basque Health ServiceCompleted
-
Emory UniversityNational Cancer Institute (NCI); National Center for Complementary and Integrative...RecruitingLymphoma | Multiple MyelomaUnited States
-
Fundación Española de Hematología y HemoterapíaRecruitingPurpura, ThrombocytopenicSpain
-
University of SurreySurrey and Borders Partnership NHS Foundation Trust; Mind and Life EuropeCompletedPersistent Depressive DisorderUnited Kingdom
-
University of Colorado, DenverUniversity of New MexicoCompletedCardiovascular DiseasesUnited States
-
Boston Children's HospitalKlick HealthUnknownInflammatory Bowel Diseases | Gastrointestinal DiseaseUnited States
-
Vastra Gotaland RegionCompletedMusculoskeletal Pain
-
Emory UniversityUnited States Department of DefenseCompletedProstate CancerUnited States
-
Laval UniversityGlaxoSmithKline; Canadian Lung AssociationTerminated